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OBJECTIVES: To evaluate the impact on costs of treating complications derived from 
chronic kidney disease (CKD) in patients undergoing hemodialysis in the private health 
care system in Brazil. METHODS: Owing to the lack of local databases, a survey with 
experts was conducted to collect data about the main causes of hospital admissions 
which resulted from complications during the dialysis period of CKD patients. A uni-
verse of 600 patients from reference centers in Brazil was studied. Later, the experts 
answered to a questionnaire about the procedures needed to manage complications. 
Then, a micro-costing was performed, only direct costs were considered: length of 
staying, medical procedures, physician fees and drugs. Sources used for costing were: 
CBHPM 2009 v.5 (physicians fees list), Revista Kairos (January 2009) (drugs price 
list) and Guia Farmacêutico Brasíndice (January 2009) (materials price list). The time 
horizon of this analysis was 1 year, thus no discount rate was assumed. The perspective 
assumed was that of the private payer. RESULTS: The 3 most frequent causes of 
hospital admissions and their respective costs in the studied centers were: cardiac 
complications (33.27%; R$3799); infections (31.90%; R$3508); and venous access 
complications (9.20%; R$2268). For an average patient, the total costs in 1 year of 
treatment were estimated to be R$5393. CONCLUSIONS: This study suggests that 
for the 600 patients studied group the economic impact for the private payer with 
hospital admissions caused by CKD complications is signiﬁcant being as high as 
R$3236,393 in one year.
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OBJECTIVES: The ﬁnancial burden of kidney transplantation depends on many 
variables as the age of patients, available complications, success rate, introduction of 
new medicines etc. The objective is to analyze the pharmacotherapy cost of patients 
with kidney transplantation in Bulgaria during 2006–2009. METHODS: It was col-
lected information for all patients with kidney transplantation during 2006–2009. Out 
of 523 transplantated patients (n  520) were included in the observation. The patient 
sample was systematized according to patient age, gender, medicines used for main 
and supporting therapy, monthly and yearly cost of pharmacotherapy. RESULTS: 
Thirty-six percent (n  189) are female and 64% (n  331) are male. Prevailing part 
of patients are among 31 to 50 years old (n  264; 51%). Below 20 years are 7 patients 
and up to 70 years are 6 ones. The standard therapy includes a combination of 
immunosuppressants. In the prevailing part of the patients were prescribes ciclosporin 
A or sirolimus in combination with azathioprine or mycophenolic acid. In case of 
allograft rejection the thymoglobulin is used and in case of HBV infection is used 
lamivudine. The CMV therapy is performed with gancyclovir. The monthly cost of 
therapy during the ﬁrst year of observation is varying among 8.29–a1276 for 354 of 
the patients, while the monthly cost at the end of the period was 9.08–a931.81 for 
a374 of the patients. The yearly cost of pharmacotherapy was found to vary on 
average from 3973 to 4325 per treated patient but the drop out level was high. 
CONCLUSIONS: Most of the modern medicines have been found prescribed in the 
collected sample with a tendency for new medicines inclusion early after their market 
launch. The main dominants of the pharmacotherapy cost changes are the availability 
of infections, followed by the kidney rejection risk, and new medicines appearance on 
the local market.
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OBJECTIVES: No research has comprehensively examined the cost-effectiveness 
between the phosphate binders within the CKD marketplace. Therefore, a model was 
developed to evaluate the cost-effectiveness of Fosrenol® (lanthanum carbonate), 
 relative to other second tier agents, Renagel®/Renvela® (sevelamer hydrochloride/ 
sevelamer carbonate), for the treatment of hyperphosphatemia in CKD. METHODS: 
A cost-effectiveness model was constructed from a managed care perspective. Two 
different time horizons including 1 day and 1 year were considered. Model inputs 
were AWP, DACON, phosphate binding capacity, and percent of patients with phos-
phorous control. Comparators included lanthanum carbonate (1,000 mg), sevelamer 
hydrochloride (800 mg), and sevelamer carbonate (800 mg). Model outcomes con-
sisted of the cost per phosphate bound daily and the cost per successfully controlled 
patient. Two break-even analyses were examined adjusting for the daily cost and 
percent of successfully controlled patients based on the most cost-effective agent. 
RESULTS: Lanthanum carbonate has a lower DACON (3.3) compared with sevelamer 
hydrochloride (8.2) and sevelamer carbonate (8.2) yet results in a greater amount of 
phosphate bound daily (514.8 mg versus 236.2 mg and 236.2 mg). This translates 
into $0.03 per 1 gm of phosphate bound daily as compared to $0.07 for sevelamer 
hydrochloride and $0.06 sevelamer carbonate. The daily cost of lanthanum carbonate 
would need to increase between 114–167% for the cost per phosphate bound to be 
equivalent to sevelamer carbonate or sevelamer hydrochloride. The yearly cost per 
successful treatment was $7,542 with lanthanum carbonate, $17,476 with sevelamer 
hydrochloride, and $13,981 with sevelamer carbonate. The percent of successfully 
controlled patients treated with sevelamer carbonate or sevelamer hydrochloride 
would need to increase 85%–131% for the cost per successfully controlled patient to 
be equivalent to lanthanum carbonate. CONCLUSIONS: These results suggest lan-
thanum carbonate is a cost-effective phosphate binder in the treatment of hyperphos-
phatemia among CKD patients relative to other second line agents.
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OBJECTIVES: This study aims to assess the cost-effectiveness of open colposuspen-
sion (OC) and two suburethral sling techniques: the tension free vaginal tape (tension-
free vaginal tape (TVT)) and the transobturator tape (transobturator tape (TOT)) in 
colombian women. METHODS: As part of a clinical practice guideline development 
we conducted a review of literature to identify effectiveness measures for the proce-
dures and complications for each one. To represent recurrent states of SUI, we created 
a Markov model. Three interventions were evaluated in four stages (continence, 
relapse-retreatment, incontinence and dead). Some assumptions were introduced (e.g. 
relapse for open colposuspension treated with vaginal tapes, TVT with TOT and TOT 
with TVT, two different scenarios with continent improvement). We programmed 
model to 85 years with a model entrance in 45 years. We used a discount rate of 3% 
for cost and effects (DALY: Disability-adjusted life year). All direct costs were 
extracted from SOAT price list. We calculated incremental cost-effectiveness ratio 
(ICER), generated efﬁciency and affordability curves. CE threshold was Gross domes-
tic product (GDP) (3619/USD). All Colombian pesos were converted to dollars apply-
ing the following rate (2100pesos/1USD). Sensitivity analysis was done. All analysis 
were performed in Treeage Pro. RESULTS: In spite the most effective alternative is 
TVT, this is the most expensive. CE threshold for TOT was US$815 and TVT was 
US$948 per procedure and no more than US$2875 per each women treated. ICER 
for TVT and TOT comparing with OC was 9720 and 45140 US$/AVAD, without 
discount, exceeding GDP threshold. Discounted ICER´s were higher. CONCLU-
SIONS: Open colposuspension remained more CE than other alternatives. Less than 
US$2857 per each women treated can improve CE for TOT and TVT and reduces 
their ICER. Cost-effectiveness evaluation for introducing health technology and clini-
cal practice guidelines must be developed in our country.
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OBJECTIVES: To explore whether combination therapy (COMBO) with dutasteride 
and tamsulosin, provides meaningful additional beneﬁts compared to each individual 
therapy or watchful waiting (WW). METHODS: COMBAT, a randomized, double-
blind, parallel group study investigating the efﬁcacy and safety of dutasteride (0.5 mg) 
and tamsulosin (0.4 mg), administered once daily for four years, alone and in 
COMBO, in symptomatic BPH patients. A Markov model was developed comparing 
the monotherapies, COMBO, and a watchful waiting (WW) reference group. The 
model evaluated the treatment costs and quality adjusted life years (QALY) at four 
yrs and lifetime based on the efﬁcacy results of COMBAT. Incremental cost effective-
ness ratios (ICER) were calculated using WW as the basis of comparison. One way 
sensitivity analyses were conducted in addition to the basecase analysis. RESULTS: 
Four years: ICER results for the COMBO and dutasteride arms were similar and 
higher than the tamsulosin arm, as the reduction in BPH progression events could not 
offset the higher drug costs. Overall, the QALY beneﬁts of the COMBO and dutaste-
ride arms were greater than the tamsulosin arm. Lifetime: ICERs decrease from those 
estimated at 4 yrs. COMBO beneﬁts become apparent in this extended time horizon. 
Follow-up and BPH progression costs of the monotherapies outweigh the higher initial 
drug cost of COMBO, in addition monitoring costs are lower for COMBO than for 
either of the MONOs or WW. The difference in event costs is indicative of lower BPH 
progression events in COMBO arm. CONCLUSIONS: Results at both time horizons 
indicate that the combination of dutasteride with tamsulosin for BPH provides gains 
in QALYs over WW and monotherapy arms, and acceptable cost effectiveness ratios 
compared to WW and the monotherapy arms. The availability of a ﬁxed dose 
COMBO, priced the same as dutasteride monotherapy could provide substantial 
health care beneﬁts to patients and cost savings to the health care system.
